CHAMPIONS ONCOLOGY, INC.
Close on Oct 19, 2026
- Market cap
- $65.18M
- P/E (TTM)
- –
- Dividend yield
- –
About Champions Oncology
Biological Products, (No Diagnostic Substances), SIC 2836
Champions Oncology, Inc. is a technology-enabled research company that develops computational and experimental platforms to assist in oncology drug discovery and development. The company operates through core business activities that include providing translational research services, licensing proprietary oncology data, and offering software subscriptions. Its offerings feature preclinical pharmacology studies using an extensive bank of patient-derived xenograft models, target discovery services, and Lumin Bioinformatics, a software-as-a-service analytical tool. Champions Oncology primarily serves biotechnology and pharmaceutical companies, as well as cancer research scientists, seeking to identify therapeutic targets and evaluate experimental treatments.
The company conducts studies for approximately 500 pharmaceutical and biotechnology clients across North America, Europe, and Asia. Its operations employ 214 full-time personnel, with a dedicated direct sales team of approximately 45 professionals. Champions Oncology maintains laboratory and research facilities situated in Rockville, Maryland, which also serves as the location of its operational suites.
Summary of the business section of Champions Oncology's latest annual report, written by StockData.
Company profile
Company
- Legal name
- CHAMPIONS ONCOLOGY, INC.
- Founded
- 1985
- Headquarters
- Baltimore, MD
- Address
- 855 N. Wolfe Street, Suite 619 21205
- Phone
- (410) 369-0365
- Website
- championsoncology.com
- Employees
- 214, Apr 30, 2026
- Industry
- Biological Products, (No Diagnostic Substances)
- Incorporated in
- Delaware
- Fiscal year ends
- April 30
- Auditor
- EISNERAMPER LLP, Iselin, New Jersey
Stock & identifiers
- Ticker
- CSBR
- Exchange
- Nasdaq
- IPO date
- Feb 2, 2007
- Shares outstanding
- 14M, Sep 9, 2026
- Public float
- $28.60M, Oct 31, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-12 reverse, Sep 11, 2015; 1-for-12 reverse, Aug 12, 2015
- SEC CIK
- 771856
- CUSIP
- 15870P307
- ISIN
- US15870P3073
- LEI
- 549300O8WKLP8QEG5U47
- EIN
- 52-1401755
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Robert Lawrence Brainin | CEO, Director | – |
| David Sidransky | Director | 767,043 |
| Scott R. Tobin | Director | 2,041,882 |
| Joel Ackerman | Director | 1,056,539 |
| Daniel Newman Mendelson | Director | 298,625 |
| Philip P. Breitfeld | Director | 5,717 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2026 Dr.Morris | $233.33K | $233.33K | $388.46K | – | $121 |
| FY2026 Mr.Brainin | $3.57M | $2.64M | $388.46K | – | $121 |
| FY2025 Ronnie Morris | $600.00K | $600.00K | $243.93K | – | $145 |
| FY2024 Ronnie Morris | $400.00K | $400.00K | $803.11K | – | $99 |
| FY2023 Ronnie Morris | $600.00K | $600.00K | $294.30K | – | $-136 |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of July 15, 2026, we had 214 full-time employees, including 103 with doctoral or other advanced degrees.”
Corporate history
Events identified from SEC filings